About
33
Publications
4,710
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
252
Citations
Introduction
Additional affiliations
January 2020 - present
December 2017 - April 2019
September 2015 - June 2017
Publications
Publications (33)
Alterations in the biological activity of the molecules under stress conditions have not been documented as widely in the literature yet. This study was designed to reveal the functional impacts of various oxidation conditions on a model mAb, a commercial anti-VEGF IgG molecule. The responses to antigen binding, cell proliferation, FcRn receptors,...
Background:
Our previous study explored the molecular signatures of generalized aggressive periodontitis (GAgP) using gingival tissues through omics-based-whole-genome transcriptomic analysis. This continuation study aimed to investigate the whole protein profiling of these gingival samples through liquid chromatography-mass spectroscopy/mass spec...
Alzheimer's disease (AD) is one of the most prevalent diseases that lead to memory deficiencies, severe behavioral abnormalities, and ultimately death. The need for more appropriate treatment of AD continues, and remains a sought-after goal. Previous studies showed palmatine (PAL), an isoquinoline alkaloid, might have the potential for combating AD...
Fc γ receptors (FcγRs) are one of the structures that can initiate effector function for monoclonal antibodies. FcγRIa has the highest affinity toward IgG1-type monoclonal antibodies among all FcγRs. In this study, a comprehensive characterization was performed for FcγRIa as a potential affinity ligand for IgG1-type monoclonal antibody binding. The...
Avastin® is a humanized recombinant monoclonal antibody used to treat cancer by targeting VEGF-A to inhibit angiogenesis. SIMAB054, an Avastin® biosimilar candidate developed in this study, showed a different charge variant profile than its innovator. Thus, it is fractionated into acidic, main, and basic isoforms and collected physically by Cation...
Bevacizumab is a humanized therapeutic monoclonal antibody used to reduce angiogenesis, a hallmark of cancer, by binding to VEGF-A. Many pharmaceutical companies have developed biosimilars of Bevacizumab in the last decade. The official reports provided by the FDA and EMA summarize the analytical performance of biosimilars as compared to the origin...
Background
Alzheimer’s disease (AD) is one of the most prevalent diseases with rapidly increasing numbers, but there is still no medication to treat or stop the disease. Previous data on coumarins suggests that scopoletin may have potential benefits in AD.
Objective
Evaluate the therapeutic potential of the coumarins with natural origin - scopolet...
The similarity between originator and biosimilar monoclonal antibody candidates are rigorously assessed based on primary, secondary, tertiary, quaternary structures, and biological functions. Minor differences in such parameters may alter target-binding, potency, efficacy, or half-life of the molecule. The charge heterogeneity analysis is a prerequ...
Background: Alzheimer's disease is one of the leading health problems characterized by the accumulation of Aβ and hyperphosphorylated tau that accounts for the senile plaque formations causing extensive cognitive decline. Many of the clinical diagnostics of Alzheimer's disease were made in the late stages where the pathological changes had already...
Alzheimer Hastalığı (AH), yaşlılarda görülen demansın en yaygın formu olup, bilişsel bozulma, ileri davranışsal bozukluklar ve ölüm ile karakterize nörodejeneratif bir hastalıktır. Dünyada en sık görülen ölüm sebeplerinde 5. sıradadır ve hala hastalığın ilerleyişini durduran ya da tersine çeviren bir tedavi bulunmamaktadır[1]. Teşhisin büyük çoğunl...
Background
CA1 subregion of the hippocampal formation is one of the primarily affected structures in AD, yet not much is known about proteome alterations in the extracellular milieu of this region.
Objective
In this study, we aimed to identify the protein expression alterations throughout the pre-pathological, progression and pathological stages o...
Indolamine melatonin structurally resembles non-covalent proteasome inhibitors; however, the role of ubiquitin proteasome system (UPS) in neuronal survival and how melatonin carries out UPS inhibition remain largely unknown. With the use of melatonin treated cells, we evaluated the expression of Nedd4-1, an E3 ligase, how melatonin regulates its ac...
Alzheimer Hastalığı (AH), hafıza kaybı ve bilişsel bozukluk ile karakterize nörodejeneratif bir hastalıktır. 2050 yılına kadar hastaların sayısının 130 milyonu geçeceği tahmin edilmektedir. AH ilerleyici bir hastalıktır ve hastaların büyük çoğunluğu sürekli bakıma ihtiyaç duymaktadır. Bu yüzden hastalığın semptomlarını azaltıcı veya durdurucu tedav...
Background
To elucidate molecular signatures of chronic periodontitis (CP) using gingival tissue samples through omics‐based whole‐genome transcriptomic and whole protein profiling.
Methods
Gingival tissues from 18 CP and 25 controls were analysed using gene expression microarrays to identify gene expression patterns and the proteins isolated from...
Alzheimer Hastalığı (AH) %70 oranıyla demansın en yaygın formu olup, davranış bozuklukları ve ölümle karakterize nörodejeneratif bir hastalıktır. Günümüzde AH tedavisi, sadece bilişsel kaybı önlemeye yönelik olup, ilerlemesini yavaşlatacak ve ya durduracak tedavi mevcut değildir. 2003 yılından beri FDA tarafından yeni bir ilaç onaylanmamıştır. Anca...
Alzheimer Hastalığı (AH), hafıza kaybı ve bilişsel bozukluk ile karakterize nörodejeneratif bir hastalıktır. Son verilerde dünyada yaklaşık 50 milyon kişinin Alzheimer hastası olduğu bildirilmiştir ve 2050 yılına kadar hastaların sayısının 130 milyonu geçeceği tahmin edilmektedir. AH ilerleyici bir hastalıktır ve hastaların büyük çoğunluğu sürekli...
Huntington Hastalığı(HH), HTT geninde bulunan CAG tekrarlarının artmasıyla oluşan ve otozomal dominant kalıtılan nörodejeneratif bir hastalıktır. Önceki çalışmalarda hastalığın mekanizması genetik araştırmalarla aydınlatılmıştır. Proteomik alanda yapılan çalışmaların sayısı az olmakla birlikte MALDI-MS görüntüleme tekniği kullanılarak HH mekanizmas...
Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by memory loss and cognitive decline (1). It is estimated that in 2016, 50 million people in the world are Alzheimer's and that by 2050 the number of patients will exceed 130 million. AD is a progressive disease, and the vast majority of patients with AD require constant care. T...
Alzheimer’s disease (AD) is the most common form of dementia (%70). Current drug treatments aim to prevent cognitive decline. No drug have been approved by FDA since 2003. Studies have revealed that alkaloids with anticholinesterase activity are a promising resource in drug discovery.[1] The aim of this project is to discover natural compounds for...
Background and Objective: Antimycin A (AntA) is a potent Electron Transport System (ETS) inhibitor exerting its effect through inhibiting the transfer of the electrons by binding to the quinone reduction site of the cytochrome bc1 complex (Complex III), which is known to be impaired in Huntington’s Disease (HD). The current studies were undertaken...
Multiple sclerosis (MS) often starts in the form of clinically isolated syndrome (CIS) and only some of the CIS patients progress to relapsing-remitting MS (RRMS). Biomarkers to predict conversion from CIS to MS are thus greatly needed for making correct treatment decisions. To identify a predictive cerebrospinal fluid (CSF) protein, we analyzed th...
Alzheimer Hastalığı (AH) %70 oranıyla demansın en yaygın formu olup, davranış bozuklukları ve ölümle karakterize nörodejeneratif bir hastalıktır. Günümüzde AH tedavisi, sadece bilişsel kaybı önlemeye yönelik olup, ilerlemesini yavaşlatacak ve ya durduracak tedavi mevcut değildir. 2003 yılından beri FDA tarafından yeni bir ilaç onaylanmamıştır. Anca...
Network of co-regulated proteins in cortex, hippocampus and cerebellum is shown in relation with inflammation pathway. (Purple: Inflammation related proteins, Green: Downregulated proteins, Red: Upregulated proteins)
Differential expression analysis of protein abundances in 5XFAD and LM brains. List of proteins with significantly altered protein abundances (> 1.5-fold change; p < 0.05) in AD versus LM brain is provided with peptide counts, confidence scores, p values and maximum fold changes. Differentially expressed proteins in the cortex, hippocampus, and cer...
Top upstream regulators of co-regulated proteins in cortex, hippocampus and, cerebellum.
Alzheimer’s disease (AD) is a progressive disorder characterized by a variety of molecular pathologies causing
cortical dementia with a prominent memory deficit. Formation of the pathology, which begins decades before the diagnosis of the disease, is highly correlated with the clinical symptoms. Several proteomics studies were performed using anima...
Occurrence of stroke cases displays a time-of-day variation in human. However, the mechanism linking circadian rhythm to the internal response mechanisms against pathophysiological events after ischemic stroke remained largely unknown. To this end, temporal changes in the susceptibility to ischemia/reperfusion (I/R) injury were investigated in mice...
In recent years, an increasing number of research papers revealed that the compositional and volumetric alterations in the extracellular matrix are the consequences of aging and may be related to Alzheimer’s disease (AD). In this study, we aimed to demonstrate the alterations in hippocampal extracellular fluid proteins in vivo using the 5XFAD mouse...
Background / Aim: Recent studies revealed that the brain extracellular matrix (ECM) molecules have several roles on the synaptic response and the stabilization of synaptic connectivity in Alzheimer’s Disease (AD). In order to investigate the role of ECM in the genesis and progression of the disease, we analyzed the proteome alterations in the hippo...
